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Abstract
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated
pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of
response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).
Methods: Gene expression was measured in patients with febrile SJIA and in matched healthy controls by Affymetrix
DNA microarrays. Transcriptional response was assessed by gene expression changes from baseline to day 3 using
adapted JIA American College of Rheumatology (aACR) response criteria (50 aACR JIA). Changes in pro-inflammatory
cytokines IL-6 and IL-18 were assessed up to day 197.
Results: Microarray analysis identified 984 probe sets differentially expressed (≥2-fold difference; P < 0.05) in patients
versus controls. Over 50% of patients with ≥50 aACR JIA were recognizable by baseline expression values. Analysis of
gene expression profiles from patients achieving ≥50 aACR JIA response at day 15 identified 102 probe sets differentially
expressed upon treatment (≥2-fold difference; P < 0.05) on day 3 versus baseline, including IL-1β, IL-1 receptors (IL1-R1
and IL1-R2), IL-1 receptor accessory protein (IL1-RAP), and IL-6. The strongest clinical response was observed in patients
with higher baseline expression of dysregulated genes and a strong transcriptional response on day 3. IL-6 declined by
day 3 (≥8-fold decline; P < 0.0001) and remained suppressed. IL-18 declined on day 57 (≥1.5-fold decline, P≤ 0.002).
Conclusions: Treatment with canakinumab in SJIA patients resulted in downregulation of innate immune response
genes and reductions in IL-6 and clinical symptoms. Additional research is needed to investigate potential differences in
the disease mechanisms in patients with heterogeneous gene transcription profiles.
Trial registration: Clinicaltrials.gov: NCT00886769 (trial 1). Registered on 22 April 2009; NCT00889863 (trial 2). Registered
on 21 April 2009.
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Background
Systemic juvenile idiopathic arthritis (SJIA) is a rare, mul-
tigenic, autoinflammatory disease of unknown etiology
characterized by chronic arthritis; intermittent high-
spiking fever, rash, and elevated levels of acute-phase reac-
tants [1–3]. The clinical course is highly variable, ranging
from a monocyclic course with a single episode of active
disease to the more common persistent clinical course in
which the disease remains clinically active. In a minority
of patients, the disease follows a polycyclic course, with
periods of quiescent disease interrupted by flares of sys-
temic features and mild arthritis [3–5].
SJIA is currently recognized as a distinct subtype of ju-
venile idiopathic arthritis (JIA), although it is unique
among the various forms of JIA in both its epidemiologic
and immunopathologic features [1–3]. In contrast to the
other JIA phenotypes, which are characterized by abnor-
malities in adaptive immune response, SJIA is driven by
dysregulation of innate immune pathways, with mono-
cytes and neutrophils—rather than lymphocytes—acting
as the predominant effector cells [3]. The innate immune
signature and clinical features of SJIA, also known as Still’s
disease, bear a striking resemblance to adult onset Still’s
disease, a rare autoinflammatory disorder characterized by
daily spiking temperature, maculopapular rash, and arth-
ritis [6]. Indeed, it has been suggested that these two clin-
ical phenotypes are part of the same disease continuum
with different ages of onset [6, 7].
A substantial and growing body of evidence suggests that
the pro-inflammatory cytokines interleukins 1, 6, and 18
(IL-1, IL-6, IL-18), and tumor necrosis factor play central
roles in the aberrant innate immune response observed in
SJIA. In vitro exposure of healthy donor peripheral blood
mononuclear cells (PBMCs) to sera from subjects with
SJIA induces transcription of genes associated with the IL-
1 signaling pathway and markedly increases IL-1β protein
secretion [8]. Additionally, treatment of patients with SJIA
with agents that block IL-1 signaling pathways resolves
clinical symptoms with corresponding improvements in la-
boratory markers of inflammation [8–14]. Finally, it was
recently reported that the proteomics signature associated
with disease flares in patients with SJIA is characterized by
the differential expression of a small group of proteins that
are centrally mediated by IL-1 [15].
Canakinumab is a high-affinity human IL-1β
monoclonal antibody that selectively binds to human
IL-1β, thereby inactivating IL-1β signaling pathways
and neutralizing its downstream effects [16, 17].
Clinical evidence of the efficacy and safety of canaki-
numab in patients with SJIA was demonstrated in
two international phase-3 trials that served as the
basis for the approval of canakinumab for the treat-
ment of SJIA by United States and European regula-
tory authorities [13, 18, 19].
In the present analysis, we sought to characterize the
molecular response to treatment with canakinumab and
explore potential markers of disease activity and thera-
peutic response in patients with SJIA using blood-
derived biomarker samples from the two phase-3 trials.
Methods
Patients
The source population for the biomarker analyses included
all patients enrolled in the two phase-3 trials evaluating
canakinumab for SJIA (ClinicalTrials.gov, NCT00886769
(trial 1) and NCT00889863 (trial 2)) conducted by the
members of the Pediatric Rheumatology International
Trials Organization (PRINTO) and the Pediatric Rheuma-
tology Collaborative Study Group (PRCSG) [13]. All pa-
tients with available samples who received treatment with
either canakinumab or placebo in trial 1 or who were
treated with canakinumab in the open-label phase of trial 2
were selected for inclusion in the biomarker study. For
selected biomarker analyses, donor samples from age-
matched, race-matched, and gender-matched healthy sub-
jects were used as a comparator.
Eligibility criteria and study designs for the original
phase-3 trials have been previously described [13].
Briefly, eligible subjects were 2 to 19 years of age with a
confirmed diagnosis of SJIA according to published cri-
teria, and who had fever [20]. Concomitant therapy with
a prednisone equivalent (up to 1.0 mg/kg/day) and stable
doses of nonsteroidal anti-inflammatory drugs and
methotrexate (≤20 mg/m2 per week) were permitted.
The studies (trials 1 and 2) were conducted according
to the ethical principles of the Declaration of Helsinki.
The study was approved by the ethics committee of all
participating centers according to the local regulations
(see SJIA gene expression ethics approval.docx).
Study design
In trial 1, patients were randomly assigned to receive a
single subcutaneous dose of canakinumab (4 mg/kg) or
matched placebo. In trial 2, patients were treated with
subcutaneous canakinumab (4 mg/kg) every 4 weeks for
up to 32 weeks during an initial open-label phase. Pa-
tients who achieved a 30 aACR JIA response (defined as
improvement of ≥30% in at least three of the six core
criteria for JIA, worsening of >30% in no more than one
of the criteria, and resolution of fever) and were not re-
ceiving glucocorticoids or who had undergone successful
tapering and were receiving a stable dose of glucocorti-
coids, were included in a second withdrawal phase in
which they were randomly assigned to continued treat-
ment with canakinumab or placebo.
Blood samples for ribonucleic acid (RNA) isolation were
collected at baseline and at day 3 in both trials. For quanti-
fication of IL-6 and IL-18, pharmacokinetic serum samples
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collected at baseline and on days 3, 29, 57, and 197 in trial
2 were used. The parent or guardian of each patient with
SJIA and each healthy volunteer provided separate written
informed consent (or assent for minors) for the collection
and analysis of blood-derived biomarkers.
Biomarker analyses
SJIA gene transcription profile
Global gene transcription was measured in whole blood
samples collected from patients with SJIA and age-
matched healthy subjects. Microarray analyses were con-
ducted by the Biomarker Development (BMD) group at
the Novartis Institutes for Biomedical Research (Basel,
Switzerland). Samples were stored at −80 °C and total
RNA was subsequently isolated using the PAXgene Blood
RNA Kit (Qiagen, Hilden, Germany). Complementary de-
oxyribonucleic acid (cDNA) was synthesized from total
RNA using the Ovation® RNA Amplification System V2
and the Ribo-SPIA® amplification process according to the
instructions of the manufacturer (NuGen Technologies
Inc., San Carlos, CA, USA). Labeled cDNA was hybridized
to GeneChip® U133plus 2.0 arrays as specified by the
manufacturer (Affymetrix, Santa Clara, CA, USA). Integ-
rity and purity of RNA and cDNA was confirmed using
the Agilent 2100 Bioanalyzer system (Agilent Technologies
Inc., Wilmington, DE, USA). Gene expression values were
derived using Affymetrix MAS 5.0 software and scaled to a
trimmed mean value of 150. Expression values were stored
in CEL files and were analyzed using Bioconductor pack-
ages or customized R-scripts [21–23].
For group-wise comparison of transcript levels, robustly
expressed transcripts were identified by filtering for probe
sets with a median expression value of at least 64 in at
least one of the groups (typically around 16,000 probe
sets). The Wilcoxon test was applied with a threshold P
value of ≤0.05 to identify genes that were significantly dif-
ferentially expressed at baseline in patients with SJIA rela-
tive to healthy controls. An additional exploratory filtering
step for effect size was performed using a 1.5-fold, 2-fold,
and 3-fold difference in the median expression value as
thresholds. The fold-change cutoffs are arbitrary and were
selected before data analysis a priori, and were intended to
either describe the more global changes in gene expres-
sion or to focus on the most strongly affected genes. Glo-
bal changes in gene expression were evaluated using the
more sensitive threshold of a 1.5-fold difference to facili-
tate identification of “hits” to signaling pathways (accept-
ing a presumably elevated false positive rate), while the
more rigorous threshold of a 3-fold difference was used to
identify the most promising biomarker candidates. No
correction for multiple comparisons was performed.
Differentially expressed transcripts were displayed using
unsupervised two-dimensional hierarchical clustering to
group baseline SJIA samples and healthy controls according
to gene expression profiles. Expression values were median-
centered per gene. Genes with a ≥1.5-fold median increase
in baseline SJIA samples relative to normal controls were
mapped to protein interaction networks using
METACORE™ pathway maps (Thompson Reuters, New
York, NY, USA).
Early transcriptional response to canakinumab
The early transcriptional response to canakinumab was
evaluated by comparing gene expression values in patients
with SJIA at day 3 with the values measured at baseline.
The magnitude of effect was expressed as the median of
the per-patient fold changes in transcription levels at day
3 compared with baseline. Differentially expressed tran-
scripts were identified using the paired sample t test (P
value ≤0.05, ≥1.5-fold differential expression). One-
dimensional hierarchical clustering of transcripts was used
to display gene expression values ordered according to the
aACR JIA response at day 15 to visualize the relationship
between baseline gene expression, day 3 transcriptional
response, and day 15 clinical response (see Additional file
1: Table S1 for the criteria for each level of response).
The data discussed in this publication have been de-
posited in the NCBI Gene Expression Omnibus and are
accessible through GEO [GEO:GSE80060] (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wdyteyw
qfbuzvgf&acc = GSE80060).
Protein biomarkers
A panel of peripheral blood protein markers was se-
lected for analysis based on prior evidence of their asso-
ciation with disease status in patients with SJIA [24–26].
Selected protein markers included IL-6 and IL-18, both
of which have been shown to be upregulated in SJIA.
Concentrations of IL-6 and IL-18 were quantified using
commercial immunoassay (Quantikine HS Human IL-6
Immunoassay, Catalogue No. SS600B, R&D Systems; Hu-
man IL-18 ELISA Kit, Catalogue No. 7620, MBL) validated
in human EDTA plasma; three levels of quality controls
prepared in human EDTA plasma were used to validate
the runs.
Sample preparation
Unknown samples (clinical study samples and the human
EDTA plasma sample used to prepare quality controls)
were stored at −80 °C. On the day of analysis, samples
were thawed at room temperature. Once thawed, samples
were stored at 2 − 8 °C or on ice if not immediately ana-
lyzed. A minimum dilution of 1:5 was applied for the ana-
lysis of IL-18.
Results
Patients with SJIA had a median age of 9 years, 52%
were female, and 77% were white, whereas controls had
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a median age of 9 years, 50% were female, and 91% were
white. Patients were characterized by high levels of dis-
ease activity at baseline, 99.4% of 177 patients had a ju-
venile arthritis disease activity score (JADAS)-27 > 8.5,
indicating high disease activity [27].
SJIA gene transcription signature
Microarray analysis of whole blood samples collected from
patients with SJIA at the baseline study visit identified a
total of 984 probe sets with at differential expression at least
twofold compared with aged-matched healthy controls. Of
these, 704 probe sets were upregulated at least twofold and
280 downregulated at least twofold relative to controls. Un-
supervised hierarchical clustering of upregulated genes per-
fectly discriminated baseline SJIA samples from healthy
control samples (Fig. 1a). Clustering of downregulated
genes had a more heterogeneous pattern; while the majority
of patients with SJIA were grouped in a single cluster that
was separated from controls, transcription patterns for
downregulated genes in a minority of patients with SJIA
were not distinguished from healthy controls (Fig. 1b).
On examination of which genes were more strongly
expressed in patients with SJIA, the number of upregulated
genes exceeded the number of downregulated genes by
nearly 10-fold among the genes with the most marked dif-
ferences. There were 111 probe sets indicating ≥3-fold
upregulation compared with only 12 probe sets indicating
≥3-fold downregulation. Among the strongly upregulated
genes were genes that encode neutrophil-expressed proteins
like CD177, olfactomedin 4 (OLFM4) or defensin, alpha 4
(DEFA4) and several other regulators of immune function
such as tumor necrosis factor, alpha-induced protein 6
(TNFAIP6), IL-1 receptor antagonist (IL1RN), C-type lectin
domain family 4 (CLEC4D) or IL-1 receptor-associated kin-
ase 3 (IRAK3); a complete list of strongly differentially
expressed genes is available in Additional file 1: Table S2.
To further examine the functional pathways affected by
genes that were differentially expressed in baseline SJIA
samples, we mapped SJIA-induced genes (≥1.5-fold differ-
ential expression) to protein interaction networks as de-
fined in the METACORE™ database/software. Network
maps indicated a strong innate immune response, with
widespread activation of inter-related pro-inflammatory sig-
naling pathways. Figure 2 illustrates the interactions
between key signaling pathways mediated by selected pro-
inflammatory proteins, including IL-1β, IL-6, and the toll-
like receptors TLR2 and TLR4.
Early transcriptional response to canakinumab
Microarray analysis of samples from patients with SJIA
treated with canakinumab and achieving ≥50 aACR JIA
response at day 15 identified a total of 1305 probe sets
Fig. 1 Hierarchical clustering of genes that were upregulated (a) and downregulated (b) at least twofold in baseline systemic juvenile idiopathic
arthritis (SJIA) samples compared with healthy control samples. Subjects are shown in columns and genes (probe sets) are shown in rows. Relative
gene expression values are color-coded. With upregulated probe sets the hierarchical clustering of subjects perfectly segregated patients with
SJIA from healthy controls. Using downregulated genes, the majority of patients with SJIA clustered together; however, a subset of patients with
SJIA was indistinguishable from healthy controls
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indicating at least 1.5-fold differential expression between
baseline and day 3 (no other post-treatment time points
were available). These transcripts largely overlapped with
those that were dysregulated (in the opposite direction) in
baseline SJIA samples as compared with healthy donor
samples. The response to canakinumab treatment of SJIA
dysregulated genes is shown in Fig. 3, which displays sam-
ples ordered by time point (baseline or day 3) and by
aACR JIA response score on day 15. These results indi-
cated stronger dysregulation at baseline and also a stron-
ger transcriptional response to canakinumab treatment in
a majority of those patients who later (at day 15) reached
higher aACR JIA response scores.
Patients who achieved a 100 aACR JIA response at day
15 had high expression of SJIA-induced genes at baseline
and a large transcriptional response (downregulation) at
day 3, with day-3 values resembling those of healthy
controls. In contrast, patients who did not achieve a 30
aACR JIA response on day 15 had weak upregulation of
SJIA-induced genes at baseline and essentially unaltered
transcription levels on day 3.
Consistent with the observation described, the gene en-
coding IL-1β—the therapeutic target of canakinuma-
b—also had a robust transcriptional response that was
more pronounced in patients who achieved the strongest
clinical outcomes. Among patients who did not achieve a
50 aACR, the relative mean gene expression (standard de-
viation (SD)) at baseline and at day 3 was 894 (501) and
657 (248), respectively. For patients who achieved ≥50
aACR, the relative mean gene expression (SD) at baseline
and at day 3 was 1738 (780) and 735 (369), respectively.
Transcription levels were also reduced for several IL-1β-
related genes, including IL-1RN, IL-1R1, IL-1R2, and IL-
1RAP, an essential component of the IL-1 receptor
complex that is required for IL-1 signal transduction.
Protein biomarkers
Longitudinal analysis of soluble biomarkers in
canakinumab-treated patients showed a marked reduc-
tion in serum IL-6 concentration that was evident by the
first assessment at day 3 and persisted throughout the
duration of observation (Fig. 4a). A more modest reduc-
tion was observed for IL-18 serum levels following cana-
kinumab treatment. Additionally, in contrast to IL-6,
which declined rapidly following treatment, the reduc-
tion in serum concentrations of IL-18 occurred later and
was not statistically significant until day 57 (Fig. 4b).
To assess the potential utility of IL-6 and IL-18 as
markers of SJIA disease activity status, we compared
serum protein levels in patients who achieved a clinical re-
sponse that was classified as “inactive disease” with those
who had clinical evidence of active disease at the
Fig. 2 Pathway map for selected proteins encoded by genes that were upregulated in baseline systemic juvenile idiopathic arthritis (SJIA) samples. Protein
interaction networks for selected proteins that were upregulated in baseline SJIA samples compared with healthy control samples. Proteins were mapped
using Metacore™ pathway maps (Thompson Reuters, New York, NY, USA). The network displayed here represents a combination of maps for the signaling
pathways for IL-1β, IL-6, and the toll-like receptors TL2 and TL4. Small red arrows adjacent to gene/protein names indicate upregulation in SJIA. ADAM10
disintegrin and metalloproteinase domain-containing protein 10, AP-1 activator protein 1, CARD caspase recruitment domain, CASP caspase, C/EBP CCAAT/
enhancer binding protein, COX2 cyclooxlygenase-2, CREB cyclic AMP responsive element binding protein, GRB growth factor receptor-bound protein,
IL-1beta interleukin-1 beta, IL-R1 interleukin-1 receptor, IL1RN interleukin-1 receptor antagonist, IL-6 interleukin-6, IL-6R interleukin-6 receptor, sIL-6RA soluble
interleukin-6 receptor antagonist, IL6ST interleukin-6 signal transducer, IRAK interleukin receptor-associated kinase, IRF interferon regulatory factor, JAK Janus
kinase, MCPIP monocyte chemotactic protein-induced protein, MEK mitogen activated kinase kinase, MMP matrix metalloproteinase, NFκB nuclear factor-κB,
SOS son of sevenless protein, STAT signal transducer and activator of transduction, TAB TGFβ-activated kinase binding protein, TAK TGFβ-activated kinase,
TLR toll-like receptor
Brachat et al. Arthritis Research & Therapy  (2017) 19:13 Page 5 of 10
corresponding study visit. As per the modified Wallace
criteria, inactive disease was defined as absence of active
arthritis, fever, and signs or symptoms of SJIA; normal C-
reactive protein level; and physician’s global assessment of
disease activity ≤10 mm) [28].
Statistically significant differences in serum IL-6 levels
were observed at each time point in patients with inactive
disease compared with the active disease group. At day 29
the mean IL-6 serum concentration in patients with active
disease was 24.3 pg/mL (SD 41.2), whereas in patients with
inactive disease the mean concentration was 1.4 pg/mL (SD
1.1) (P = 0.0002). Similarly at day 57 the mean IL-6 serum
concentration in patients with active disease was 25.2 (SD
31.2), whereas in patients with inactive disease, the mean
concentration was 1.5 pg/mL (SD 1.4) (P = 8.9e−6). At day
197 the mean IL-6 serum concentration in patients with ac-
tive disease was 45.0 (SD 85.7), whereas in patients with in-
active disease, the mean concentration was 1.5 pg/mL (SD
0.5) (P = 0.01). Additionally, serum IL-6 levels were normal
in all patients classified as having inactive disease; however,
normal levels were also observed in patients with active dis-
ease. Analysis of serum IL-18 concentrations showed no
statistically significant differences between patients with ac-
tive and inactive disease. At day 29 the mean serum IL-18
concentration in patients with active disease was 14080 pg/
mL (SD 26733), whereas in patients with inactive disease,
the mean concentration was 21090 pg/mL (SD 30291) (P =
0.3). At day 57 the mean IL-18 concentration in the pa-
tients with active disease was 10830 pg/mL (SD 16875),
whereas in patients with inactive disease the mean concen-
tration was 16790 pg/mL (SD 21661) (P = 0.2). At day 197
the mean IL-18 concentration in patients with active dis-
ease was 6218 pg/mL (SD 8784), whereas in patients with
inactive disease the mean concentration was 7970 pg/mL
(SD 12140) (P = 0.7).
Discussion
The current study of blood-derived biomarkers in patients
with SJIA treated with canakinumab in a phase-3 clinical
trial program yielded several observations with potential
implications for patient management and subsequent re-
search. First, analysis of global gene expression in whole
blood samples from patients with SJIA and age-matched
healthy controls identified robust disease-related alterations
of the transcriptome involving key mediators of innate im-
mune response. Consistent with prior research [29–31], dif-
ferentially expressed genes were typically upregulated
relative to healthy controls, supporting the hypothesis that
the immune-pathologic process in SJIA is characterized by
transcriptional activation of “disease genes” rather than
suppression of “health-associated” genes.
Second, we identified a canakinumab response signature
in many patients with SJIA that was characterized by the
rapid normalization of transcript levels for SJIA overex-
pressed genes, including those associated with IL-1 and IL-
6 signaling pathways. For example, we observed a marked
decline in transcription levels of the gene encoding the
therapeutic target of canakinumab, IL-1β, suggesting that
Fig. 3 Early transcriptional response to canakinumab treatment of dysregulated genes in systemic juvenile idiopathic arthritis (SJIA). Genes (probe sets) are
shown in rows and subjects are shown in columns, ordered according to disease status (SJIA versus healthy), assessment time point (baseline versus day 3),
and by response according to American College of Rheumatology (ACR) criteria at day 15. Relative gene expression values are color-coded. a Genes that
were upregulated ≥2-fold in baseline SJIA samples compared with healthy control sample. b Genes that were downregulated ≥2-fold in baseline SJIA
samples compared with healthy control samples
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canakinumab disrupts a positive feedback loop between IL-
1β signaling and IL-1β production. The strongest clinical
response to canakinumab was observed in patients with
higher baseline expression of SJIA-induced genes and a lar-
ger transcriptional reduction at day 3; poor clinical re-
sponse was typically associated with low differential
expression of dysregulated genes at baseline and a negli-
gible transcriptional response at day 3.
It is noteworthy that the group of genes comprising the
canakinumab response signature in this study closely corre-
sponds with the group of genes that define the transcription
signature of adult-onset Still’s disease (AOSD). Indeed,
comparison of baseline gene transcription data from pa-
tients with AOSD enrolled in a recent trial evaluating cana-
kinumab in healthy adult subjects showed that the mean
expression of all of the genes that were downregulated fol-
lowing canakinumab treatment in the current study were
upregulated prior to treatment in patients with AOSD rela-
tive to healthy controls (P < 0.00002) [32, 33]. Similarly,
most of the genes that were upregulated following canaki-
numab treatment in patients with SJIA were downregulated
prior to treatment in patients with AOSD compared with
healthy controls (P < 0.00002). Collectively, these findings
support the concept of a Still’s disease continuum that in-
cludes both a juvenile-onset and an adult-onset form.
Third, consistent with the early transcriptional effects of
canakinumab on genes encoding proteins involved in
innate immunity, serum concentrations of the pro-
inflammatory cytokines IL-6 and IL-18 declined following
treatment with canakinumab. While IL-6 levels declined
markedly by day 3 and remained suppressed throughout
the duration of treatment, the decline in IL-18 was less ro-
bust and occurred much later than the observed declines
in IL-6. This might be explained by slow-acting regulatory
mechanisms controlling peripheral IL-18 secretion or by
residual ongoing pro-inflammatory stimulation of un-
known origin. It is important to note that circulating levels
of IL-18 have been shown to be markedly elevated in pa-
tients with SJIA with macrophage activation syndrome
(MAS) [34–36]. While high IL-18 was observed in the
three patients who developed MAS during the phase-3
trial of canakinumab, there were quite a few patients with
a
b
Fig. 4 Longitudinal change in serum concentrations of IL-6 (a) and IL-18 (b) after treatment with canakinumab. Data are shown for trial 2.
Similar results were observed for plasma samples in trial 1 (data available until day 29; not shown). The left panel (b) shows all data; the
right panel represents a magnification of the lower portion of the y-axis. IL-6 interleukin-6, IL-18 interleukin 18
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equally high or higher IL-18 who did not develop MAS
during the course of the study. Evidence from recent stud-
ies suggests a complex interaction between IL-18 and
other cytokines in the development of MAS and provides
intriguing clues on the potential contribution of free IL-18
levels, the IL-18/IFN-γ ratio, and the IL-18/IL-6 ratio to
the prediction of MAS in patients with SJIA [35, 36]. Each
of these clues warrants further investigation; however, the
limited number of patients with MAS in this cohort pre-
cludes meaningful interpretation of the available data.
Fourth, the presence of a number of SJIA-induced
genes at baseline, e.g., CD177, OLFM4, and the gene en-
coding IL-1β, among others, appeared to lead to a stron-
ger transcriptional response to canakinumab treatment
and higher ACR responses at day 15. However, in a sig-
nificant proportion of canakinumab responders, these
transcriptional effects were not observed, and therefore,
baseline gene expression would not correctly predict
good canakinumab responders. The predictive perform-
ance of baseline gene expression, with respect to other
previously identified markers of response to IL-1 inhib-
ition, will be the subject of future investigation.
The findings of the present study should be interpreted
in the context of certain limitations. First, while the ob-
served changes in gene expression were presumably influ-
enced by changes in the cellular composition of the
samples, the precise contribution of changes in blood cell
populations to the observed transcriptional response cannot
be reliably ascertained. Additionally, the degree to which
the findings might have been influenced by factors such as
disease duration and severity, prior treatment with other
biologic therapies, and concomitant exposure to corticoste-
roids during the study is unknown. Second, baseline gene
transcription was evaluated using the single pre-treatment
blood sample that was available for each patient. Given the
dynamic nature of the disease with frequent spikes in fever,
it is possible that the differences between patients with SJIA
and healthy controls were attenuated or obscured and that
the contrast in gene transcription profiles might be en-
hanced by integrating data from multiple pre-treatment
measurements. This might also reduce the apparent hetero-
geneity observed in subgroups of patients who achieved a
comparable clinical response to canakinumab. Finally, pa-
tients without fever and with a more prominent polyarticu-
lar disease course were excluded from enrollment in the
original phase-3 clinical trials from which blood samples for
the current study were obtained. Accordingly, the effect of
canakinumab on gene expression in patients with SJIA with
a polyarticular disease course is unknown.
Conclusions
Our findings demonstrate that canakinumab treatment
in patients with SJIA results in rapid reductions in the
expression of genes related to inflammation, with
corresponding reductions in circulating levels of pro-
inflammatory cytokines and clinical symptoms, suggest-
ing that canakinumab can, at least in part, reverse mo-
lecular disease patterns.
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Collaborative Study Group; PRINTO: Pediatric Rheumatology International Trials
Organization; RNA: ribonucleic acid; SJIA: systemic juvenile idiopathic arthritis;
TNFAIP6: tumor necrosis factor, alpha-induced protein 6
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